How Will Rhythm Biosciences’ geneType™ Transform Southeast Asia’s Genetic Testing?
Rhythm Biosciences has inked a pivotal distribution agreement with UK-based Digistain Limited to introduce its geneType™ genetic test portfolio in Southeast Asia, starting with the Philippines. This marks Rhythm’s first commercial foothold in the region, setting the stage for broader expansion.
- 12-month supply and distribution agreement with Digistain Limited
- Initial launch in the Philippines with potential regional expansion
- Structured pricing and volume commitments provide revenue visibility
- Non-exclusive arrangement allows further distribution partnerships
- Partnership leverages Digistain’s established Southeast Asian network
Strategic Entry into Southeast Asia
Rhythm Biosciences Limited (ASX:RHY) has taken a significant step in its international growth strategy by signing a supply and distribution agreement with UK-based Digistain Limited. The deal grants Digistain the rights to market and distribute Rhythm’s geneType™ genetic test portfolio, with the Philippines serving as the initial launch market. This agreement represents Rhythm’s first formal commercial entry into Southeast Asia, a region identified for its large population, rising healthcare expenditure, and growing demand for advanced genetic diagnostics.
The geneType™ Platform and Market Opportunity
The geneType™ platform offers a comprehensive genetic risk assessment across multiple diseases, including various cancers and cardio-metabolic conditions. By combining clinical, family history, and genetic data, it provides personalised health insights that can guide early detection and prevention strategies. Southeast Asia’s relatively low penetration of such advanced diagnostics, coupled with improving access to private healthcare, creates a fertile environment for geneType™’s adoption.
Agreement Terms and Commercial Implications
The 12-month agreement, commencing 3 March 2026, includes a structured pricing framework and minimum volume commitments, providing Rhythm with a baseline revenue floor as the market establishes. The non-exclusive nature of the deal allows Rhythm to pursue additional distribution partners across the region, enhancing scalability. Digistain’s existing commercial infrastructure and sub-distribution networks, including ties with Precision Healthcare PTE, position it as a capable partner to accelerate geneType™’s regional rollout.
Leadership Perspectives
David Atkins, Rhythm’s CEO, described the agreement as a “meaningful step” towards translating geneType™ into commercial test volumes and highlighted Southeast Asia’s long-term potential. Dr Hemmel Amrania, CEO of Digistain, emphasised the growing clinical and consumer demand for genetic risk testing in the region and expressed enthusiasm about adding geneType™ to their portfolio.
Looking Ahead
Operational onboarding is underway, including training Digistain personnel and finalising sample logistics. Rhythm plans to provide updates as commercial activity gains momentum and as additional Southeast Asian markets are activated. While specific revenue forecasts remain cautious due to the early-stage nature of the launch, this partnership lays a solid foundation for Rhythm’s regional growth ambitions.
Bottom Line?
Rhythm’s Southeast Asia debut with Digistain sets a promising foundation for scaling geneType™ across a high-growth market.
Questions in the middle?
- How quickly will geneType™ gain traction among clinicians and patients in the Philippines?
- Which additional Southeast Asian markets might Rhythm target next through this partnership?
- What are the potential competitive challenges in the region’s genetic diagnostics landscape?
